PriceTargets.com logo

Gamida Cell - GMDA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 04/5/2024 05:00 PM ET
+0 (0.00%)
Get New Gamida Cell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMDA

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Gamida Cell in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for GMDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Gamida Cell. This rating has held steady since January 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/29/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Perform
12/5/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00
11/15/2023Piper SandlerLower TargetOverweight ➝ Overweight$5.00 ➝ $2.00
11/15/2023HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $5.00
9/28/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$6.00
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$11.00
8/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00
5/19/2023JMP SecuritiesLower Target$8.00 ➝ $6.00
4/20/2023Needham & Company LLCLower TargetBuy$8.00 ➝ $6.00
4/19/2023HC WainwrightBoost TargetBuy$5.00 ➝ $11.00
3/28/2023HC WainwrightLower TargetBuy$22.00 ➝ $5.00
3/27/2023OppenheimerLower TargetOutperform$10.00 ➝ $8.00
11/22/2022Needham & Company LLCLower TargetBuy$9.00 ➝ $8.00
11/15/2022OppenheimerLower TargetOutperform$15.00 ➝ $10.00
10/3/2022Piper SandlerLower TargetOverweight ➝ Overweight$8.00 ➝ $7.00
9/29/2022Needham & Company LLCLower TargetBuy$12.00 ➝ $9.00
8/15/2022Piper SandlerBoost Target$6.00 ➝ $8.00
6/2/2022JMP SecuritiesReiterated RatingBuy$17.00
5/10/2022Piper SandlerLower Target$13.00 ➝ $6.00
3/16/2022HC WainwrightReiterated RatingBuy$22.00
2/1/2022JMP SecuritiesReiterated RatingBuy$17.00
11/16/2021HC WainwrightLower TargetBuy$27.00 ➝ $22.00
11/16/2021Needham & Company LLCLower TargetBuy$14.00 ➝ $12.00
11/16/2021Piper SandlerLower TargetOverweight ➝ Overweight$23.00 ➝ $13.00
11/16/2021OppenheimerLower TargetHold ➝ Outperform$17.00 ➝ $15.00
11/1/2021Alliance Global PartnersInitiated CoverageBuy$11.00
3/9/2021Piper SandlerLower Target$25.00 ➝ $23.00
3/9/2021Needham & Company LLCLower TargetBuy$17.00 ➝ $14.00
2/10/2021HC WainwrightBoost TargetPositive ➝ Buy$15.00 ➝ $27.00
2/9/2021OppenheimerReiterated RatingBuy$17.00
12/14/2020OppenheimerLower TargetOutperform$20.00 ➝ $17.00
12/6/2020OppenheimerInitiated CoverageBuy$20.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Gamida Cell logo
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.17
Low: $0.01
High: $0.40

52 Week Range

Now: N/A

Volume

23,036,800 shs

Average Volume

9,201,723 shs

Market Capitalization

$5.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Gamida Cell?

The following Wall Street analysts have issued research reports on Gamida Cell in the last twelve months:
View the latest analyst ratings for GMDA.

What is the current price target for Gamida Cell?

0 Wall Street analysts have set twelve-month price targets for Gamida Cell in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Gamida Cell in the next year.
View the latest price targets for GMDA.

What is the current consensus analyst rating for Gamida Cell?

Gamida Cell currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GMDA.

What other companies compete with Gamida Cell?

Other companies that are similar to Gamida Cell include NKGen Biotech, Sorrento Therapeutics, SQZ Biotechnologies, Genocea Biosciences and Genocea Biosciences. Learn More about companies similar to Gamida Cell.

How do I contact Gamida Cell's investor relations team?

Gamida Cell's physical mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company's listed phone number is (713) 400-6400 and its investor relations email address is [email protected]. The official website for Gamida Cell is www.gamida-cell.com. Learn More about contacing Gamida Cell investor relations.